# SABR-COMET (NCT01446744)

> Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01446744
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Conditions: Metastatic Tumors
- Interventions: Stereotactic ablative radiotherapy; palliative radiotherapy
- Enrollment: 99
- Primary outcome: Overall Survival

## Commentary we found

- X threads: 76
- Podcasts: 18
- YouTube: 17

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=sabr-comet-nct01446744

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01446744", "email": "<work email>"}; the inbox owner confirms by the emailed link.